Your browser doesn't support javascript.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Faustini, Sian E; Hall, Andrew; Brown, Sarah; Roberts, Sadie; Hill, Harriet; Stamataki, Zania; Jenner, Matthew W; Owen, Roger G; Pratt, Guy; Cook, Gordon; Richter, Alex; Drayson, Mark T; Kaiser, Martin F; Heaney, Jennifer L J.
  • Faustini SE; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Hall A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Brown S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Roberts S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Hill H; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Stamataki Z; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Jenner MW; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Owen RG; The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Pratt G; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Cook G; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Richter A; The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Drayson MT; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Kaiser MF; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Heaney JLJ; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
Br J Haematol ; 201(5): 845-850, 2023 06.
Article in English | MEDLINE | ID: covidwho-2258844
ABSTRACT
Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Myeloma Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa Language: English Journal: Br J Haematol Year: 2023 Document Type: Article Affiliation country: Bjh.18714

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Myeloma Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa Language: English Journal: Br J Haematol Year: 2023 Document Type: Article Affiliation country: Bjh.18714